Moderna (MRNA) Operating Leases (2018 - 2026)
Moderna (MRNA) posted quarterly Operating Leases of $659.0 million for Q2 2026, down 3.37% year-over-year from $682.0 million in Q2 2025, and down 0.75% on a QoQ basis from $664.0 million in Q1 2026.
Moderna (MRNA) Operating Leases (2018 - 2026) Analysis & Trends
Moderna has reported Operating Leases for 9 years, with the latest figure at $659.0 million in Q2 2026.
- Operating Leases for Q2 2026 came in at $659.0 million, down 3.37% year-over-year; the trailing twelve-month figure through Jun 2026 was $659.0 million (down 3.37% YoY), and the FY2025 annual result was $653.0 million, down 2.68% from the prior year.
- Operating Leases retreated to $659.0 million in Q2 2026, from $664.0 million in the prior quarter.
- Over five years, Operating Leases peaked at $730.0 million in Q3 2023 and troughed at $92.0 million in Q4 2022.
- A 5-year average of $491.7 million and a median of $660.5 million in 2024 frame the typical range for Operating Leases.
- The widest annual swing landed in 2022, when Operating Leases declined 13.21%; it then surged 598.91% in 2023.
- A 5-year view of Operating Leases shows it stood at $92.0 million in 2022, then soared by 598.91% to $643.0 million in 2023, then gained by 4.35% to $671.0 million in 2024, then dropped by 2.68% to $653.0 million in 2025, then gained by 0.92% to $659.0 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $659.0 million in Q2 2026, $664.0 million in Q1 2026, and $653.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 659.00 Mn |
| Mar 31, 2026 | 645.00 Mn |
| Dec 31, 2025 | 653.00 Mn |
| Sep 30, 2025 | 677.00 Mn |
| Jun 30, 2025 | 666.00 Mn |
| Mar 31, 2025 | 667.00 Mn |
| Dec 31, 2024 | 671.00 Mn |
| Sep 30, 2024 | 679.00 Mn |
| Jun 30, 2024 | 693.00 Mn |
| Mar 31, 2024 | 662.00 Mn |
| Dec 31, 2023 | 643.00 Mn |
| Sep 30, 2023 | 697.00 Mn |
| Jun 30, 2023 | 138.00 Mn |
| Mar 31, 2023 | 124.00 Mn |
| Dec 31, 2022 | 92.00 Mn |
| Sep 30, 2022 | 115.00 Mn |
| Jun 30, 2022 | 125.00 Mn |
| Mar 31, 2022 | 95.00 Mn |
| Dec 31, 2021 | 106.00 Mn |
| Sep 30, 2021 | 127.00 Mn |